20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Pharvaris BV (PHVS) operates in the BIOTECHNOLOGY industry and is headquartered in Zug, Switzerland with about 148 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, PHVS reported €0M in revenue and (€176M) in net income.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | €0M | €0M | €0M | €0M | €0M | €0M | €0M | €0M |
| Gross Profit | — | — | — | €0M | €0M | €0M | €0M | €0M | — |
| Gross Margin % | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | (€183M) | (€170M) | (€146M) | (€97M) | (€87M) | (€54M) | (€29M) | (€9M) | (€4M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — |
| Net Income | (€172M) | (€176M) | (€134M) | (€101M) | (€76M) | (€43M) | (€30M) | (€9M) | (€4M) |
| Net Margin % | — | — | — | — | — | — | — | — | — |
| EBITDA | — | (€173M) | (€146M) | (€100M) | (€87M) | (€42M) | (€30M) | (€9M) | (€4M) |
| Earnings Per Share (EPS) | €-2.63 | €-2.97 | €-2.48 | €-2.63 | €-2.27 | €-1.41 | €-0.97 | €-0.28 | €-0.14 |
| Shares Outstanding (M) | 68M | 59M | 54M | 38M | 34M | 30M | 31M | 32M | 32M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | €0M | €0M | €0M | €0M | €0M | €0M | €0M |
| Gross Profit | €0M | €0M | — | — | — | €0M | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | (€51M) | (€45M) | (€48M) | (€40M) | (€40M) | €42M | (€45M) | (€38M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | (€48M) | (€40M) | (€47M) | (€37M) | (€45M) | (€46M) | (€35M) | (€42M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | (€51M) | (€39M) | — | (€37M) | (€45M) | (€42M) | — | (€41M) |
| Earnings Per Share (EPS) | €-0.70 | €-0.61 | €-0.72 | €-0.60 | €-0.83 | €-0.85 | €-0.64 | €-0.77 |
| Shares Outstanding (M) | 68M | 65M | 65M | 62M | 55M | 55M | 54M | 54M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | (€156M) | (€137M) | (€120M) | (€93M) | (€67M) | (€45M) | (€21M) | (€7M) | (€4M) |
| Capital Expenditures (CapEx) | €0M | €0M | €1M | €0M | €0M | €0M | €0M | €0M | €0M |
| Free Cash Flow (FCF) | (€156M) | (€137M) | (€121M) | (€93M) | (€67M) | (€45M) | (€22M) | (€7M) | (€4M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | (€38M) | (€50M) | (€38M) | (€31M) | (€30M) | (€38M) | (€35M) | (€33M) |
| Capital Expenditures (CapEx) | €0M | €0M | €0M | €0M | €0M | €0M | €0M | €0M |
| Free Cash Flow (FCF) | (€38M) | (€50M) | (€38M) | (€31M) | (€30M) | (€39M) | (€35M) | (€34M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | €329M | €301M | €291M | €399M | €168M | €212M | €101M | €21M | €5M | €5M |
| Cash & Cash Equivalents | €318M | €292M | €281M | €391M | €162M | €209M | €99M | €20M | €5M | €5M |
| Total Liabilities | €28M | €30M | €24M | €15M | €18M | €7M | €5M | €2M | €0M | €0M |
| Total Debt (Short + Long-Term) | €0M | €0M | €0M | €0M | €0M | €0M | €0M | €0M | €0M | €0M |
| Total Shareholders' Equity | €301M | €271M | €268M | €384M | €149M | €205M | €96M | €19M | €5M | €5M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PHVS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms